Navigation Links
The Lancet: 1 in 3000 blood donors in England infected with hepatitis E

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around 1200 HEV-containing blood components (eg, red cells, platelets, and fresh frozen plasma) are likely to be transfused every year in England.

The study retrospectively screened 225 000 individual blood donations collected in south east England between Oct, 2012 and Sept, 2013 for HEV RNA. 79 donors were found to be currently infected with genotype 3 HEV (that can spread directly from animals to humans)a prevalence of about 1 in 2848. The 79 donations had been used to prepare 129 blood components, 62 of which had been transfused. Follow-up of 43 exposed recipients showed transmission had occurred in 18 (42%) patients.

"HEV genotype 3 infections are widespread in the English population, including blood donors. We estimate that between 80 000 and 100 000 human HEV infections are likely to have occurred in England during the year of our study", principal investigator Professor Richard Tedder from the Blood Borne Virus Unit at Public Health England, explained.

"Although rarely causing any acute illness, hepatitis E infections may become persistent in immunosuppressed patients, putting them at risk of future chronic liver disease, and a policy is needed to identify these persistently infected patients and provide them with appropriate antiviral treatment. However, our study indicates that the overall burden of harm resulting from transfusion-transmitted HEV is slight. Although on a clinical basis alone there appears no pressing need at this time for blood donations to be screened, a broader discussion over harm mitigation is now required."*

Writing in a linked Comment, Professor Jean-Michel Pawlotsky from Hpital Henri Mondor, Universit Paris-Est, Crteil, France, calls for the systematic screening of blood components for hepatitis E infection to be introduced in areas where HEV is endemic, such as the European Union.

He writes, "Despite[the] high prevalence, the high rate of transmission by infected blood or blood products, the non-negligible morbidity and mortality related to HEV infection (especially in patient populations exposed to blood or blood product transfusion), and the lack of efficient antiviral therapy, Hewitt and colleagues surprisingly conclude that "there seems no pressing need to move rapidly with the introduction of donation screening"The potential clinical results of blood-borne HEV infection should not be downplayed; in particular, the risk of serious complications and death exists. Thus, on the basis of Hewitt and colleagues' and other studies, I believe that systematic screening of blood components for markers of hepatitis E infection should be implemented in areas where HEV is endemic (eg, the European Union), based on HEV RNA detection. No doubt this position will be debated and, whatever the experts think, a political decision will have to be made. I suspect that pooled HEV RNA testing will become obligatory in blood banks soon."

Contact: Professor Richard Tedder
The Lancet

Related medicine news :

1. The Lancet: China halves tuberculosis prevalence in just 20 years
2. The Lancet: UK has one of the highest death rates for children in western Europe
3. The Lancet: Midwifery matters more than ever
4. The Lancet: New trial suggests cheaper drugs for common heart attack procedure could improve outcomes and save health budgets millions
5. The Lancet: Sierra Leone researchers call for improved health surveillance and communication around Ebola crisis
6. Infection Might Raise Blood Clot Risk for Older Adults: Study
7. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
8. Common Blood Pressure Drug Safe for Heart Failure: Study
9. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
10. High Blood Pressure May Be Especially Lethal for Blacks
11. Changes in gene expression may help explain high blood pressure in pregnancy
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... ChiliPad , Chili Technology’s temperature-controlled ... through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, recommends ChiliPad ... precisely regulates the surface temperature of each side of the bed so that ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patient centered orthopedic care. Led by John Vitolo, M.D., the center offers ... condition, the team at Advocare Orthopedic & Sports Medicine is ready to help ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... Tufts School of Dental Medicine in 1935. His father graduated from NYU School ... in dentistry as well as their commitment and passion to the Practice of Dentistry. ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently ... Poison Data System (NPDS) reveals that in 2014, someone called a poison center ... two million of which were human exposure cases. , The American Association of ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology: